UK markets closed

CytomX Therapeutics, Inc. (CTMX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
5.14-0.05 (-0.96%)
At close: 4:00PM EDT
5.14 0.00 (0.00%)
After hours: 04:33PM EDT
Sign in to post a message.
  • S
    Scott
    Curious if anyone had the chance to watch and/or listen to the webcast from the H.C. Wainwright Annual Global Investment Conference this past Monday, Sept 13th?
  • M
    Max
    Right on, $3.8-4,2 is double up time, anything below $3.8 is quadruple territory;) Patents are worth a ton and a nice surprise in research could get the rocket started anytime. Patience&good luck!
  • A
    Arts,Food&Business
    Let s buy today $$$$
  • M
    Max
    Excellent chance to get into this very promising GE company at a steep discount after some brokerage company downgraded CTMX with a pt of #$%$ an already very depressed stock price in a very oversold sector, so I regard this as a strong buying opportunity around $7. This stock could easily double or triple if they make further progress in their studies. Let's talk next year and see who was right on their call. To me it's a clear buy&hold.
  • M
    Mark
    I am interested in investing in this company, but I am leery of the JP Morgan Overweight rating. I have gotten burned on Kala, Akebia, and Orchard which all had the Overweight rating.
  • G
    George
    They have approx 7.50 a share in cash figuring the last offering. That is valuing the company @ only 1.25. Think this moves to 12 ...jmho
  • B
    BullRider
    From 8-K: On January 25, 2021, the Offering closed and the Company completed the sale and issuance of an aggregate of 14,285,714 shares of Common
    Stock. The Company received net proceeds from the Offering of approximately $93.6 million, after deducting the Underwriters’ discounts and
    commissions and estimated offering expenses payable by the Company.
  • W
    WallStreet
    When Jefferies analyst gave a 10 price, knew its coordinated short attack time.
    from twitter, to seekingalpha, to stocktwits negative news will be spread for many days. And will continue to short . current bottom 7.78 .
    7.80 to 8.20 is current CTMX valuation in cash, so we have some cushion here. but shorts often take it way below cash valuation so be ready to buy when it reverses
  • J
    Johny
    Results: 99 patients, including 45 with HR+/Her2- BC, HER2+ BC, or TNBC, were enrolled from 27 sites. The median number of prior therapies was 5.5 (range, 1-10) in all patients and 7 (3-16) in BC patients. Patients received a median of 2 (range, 1-16) CX-2009 doses. 92 patients discontinued treatment; the majority for disease progression/symptomatic deterioration (n=65) or adverse events (n=11). In 26 evaluable BC patients treated at ≥4 mg/kg, ORR was 11% (HR+/HER2-; n=18) and 38% (TNBC; n=8) including confirmed and unconfirmed responses, with a Clinical Benefit Rate at 24 weeks (CBR24) of 35%. CX-2009 remained predominantly (median >95%) in the inactive form in circulation (Stroh M, et al. J Clin Oncol. 2020; 38 [15 suppl]: abstract 3599). Over the dose range of 4-10 mg/kg, activated CX-2009 was quantifiable in 18 out of 22 biopsy samples, including 6 of 7 samples from the BC subset. The intratumoral concentrations of activated CX-2009 and CD166 were significantly correlated (r2=0.59, p=0.004). DM4 was measured in 12 evaluable biopsy samples. Levels of normalized intratumoral DM4 were significantly correlated with the relative change in target lesions (r2=0.34, p=0.045).

    In 26 evaluable BC patients treated at ≥4 mg/kg, ORR was 38% (TNBC; n=8) including confirmed and unconfirmed responses.

    In TNBC, this ORR at 38% is as good as Trodelvy.
  • S
    Scott
    CTMX is trading for close to cash on hand... Fully acknowledge CytomX is generating negative free cash flow, but there's still value in the business prospects. Share price makes no sense right now, suggest they're at least 30-50% undervalued in the short term IMO. Good luck CTMX longs!
  • S
    Sarah
    This company is majorly screwed. Around six months ago a new CDO, Amy Peterson, was brought on in order to inject new energy into the CytomX's development efforts. Peterson previously worked at Beigene, Medivation and Genentech, which all sounds great until you find out that she has been terminated by all of her previous employers because she's so difficult to work with and is known for having an abusive and atrocious management style. At Medivation she was actually escorted out of the building by security after terrorizing her staff relentlessly. Since she was hired at Cytomex there's been a massive exodus from all of the teams under her, with Cytomx losing decades of institutional knowledge. Amy Peterson leads by fear, not by inspiration and she's unleashed what many former CytomX employees refer to as a "reign of terror" on the teams under her. As a consequence of her actions CytomX is now understaffed and having a difficult time recruiting new employees, in addition to facing mounting legal costs because of the sloppy way she's terminated many existing employees. With the economy facing crisis due to COVID-19 Cytomx faces an existential crisis and my betting is this company will not exist in the same form next year, if not later this year after it fails to provide anything compelling at ASCO.
  • p
    paul
    The 10 day chart shows the golden cross happened Thursday afternoon!
    So the positive things we have going on:
    Double bottom on the 3 month chart.
    Increased volume.
    Strong institution holdings.
    Minimum shorts.
    Golden cross .
    Go CTMX!
  • S
    Scott
    Net cash on balance is about 70% of the total market cap. Company now cash flow positive.
    What's not to like in this speculative stock?
  • W
    WallStreet
    Who saw the 1.4M single block today? it means multi day uptrend is going to start. let us see how true this is.
  • J
    Johan
    Thanks for the ride.
    Now I am buying Anab.
    No debts, lot of cash, GSK soon approval with Anab molecule etc...
  • r
    robert
    @Michael. Actually there was news. Wedbush tapped ctmx as top healthcare pick for 2018 with 37 price target. Gltal.
  • J
    JORDAN B
    Anyone know why it's down hard after the bell?
  • V
    Ville
    There is still very few interest in CTMX by retail investors. That will change if/when CTMX delivers a PoC and suddenly all wake up. The door then is narrow and all want in. I am looking forward to it. 2018 will be the year.
    Ville - shareholder since June 2016
  • B
    Burton
    anybody who has been following this stock? yesterday's sell-off was way too heavy when considering: (1) the pipeline (2) the huge institutional investors which keep on adding recently, including renowned gurus such as Cohen (3) the cash available and cash burn which is very low. Was there any reason for yesterday's sell-off? I think that this represents a very good entry point with a good risk-reward ratio.
  • W
    William
    I see this as a strong buy with the latest from the BM CEO.